{"id":923,"date":"2024-02-01T14:24:40","date_gmt":"2024-02-01T14:24:29","guid":{"rendered":"https:\/\/devm.kyowakirininternational.com\/?page_id=923"},"modified":"2025-04-23T12:49:42","modified_gmt":"2025-04-23T11:49:42","slug":"news-resource","status":"publish","type":"page","link":"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/","title":{"rendered":"News &amp; Resources"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; custom_margin=&#8221;25px||-30px||false|false&#8221; global_module=&#8221;692&#8243; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#e5e5e5&#8243; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-55px||||false|false&#8221; custom_margin_tablet=&#8221;&#8221; custom_margin_phone=&#8221;&#8221; custom_margin_last_edited=&#8221;on|desktop&#8221; custom_padding=&#8221;0px|0px|0px|0px|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; admin_label=&#8221;Column&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;25px|||5px|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text content_tablet=&#8221; <\/p>\n<p style=%22text-align: center;%22><a href=%22https:\/\/www.kyowakirinhub.com\/%22 data-et-target-link=%22_blank%22 rel=%22noopener%22><span style=%22color: #ff6600;%22>Healthcare Professionals Hub<\/span><\/a><\/p>\n<p> &#8221; content_phone=&#8221;<\/p>\n<p style=%22text-align: center;%22><a href=%22https:\/\/www.kyowakirinhub.com\/%22 data-et-target-link=%22_blank%22 rel=%22noopener%22><span style=%22color: #ff6600;%22>Healthcare Professionals Hub<\/span><\/a><\/p>\n<p>&#8221; content_last_edited=&#8221;on|phone&#8221; admin_label=&#8221;Text&#8221; _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;|700|||||||&#8221; text_text_color=&#8221;#ea5504&#8243; text_orientation=&#8221;center&#8221; custom_margin=&#8221;||||false|false&#8221; custom_margin_tablet=&#8221;&#8221; custom_margin_phone=&#8221;||||false|false&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; custom_padding=&#8221;||||false|false&#8221; link_option_url_new_window=&#8221;on&#8221; text_text_color_tablet=&#8221;&#8221; text_text_color_phone=&#8221;&#8221; text_text_color_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.kyowakirinhub.com\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #ff6600;\">Healthcare Professionals Hub<\/span><\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; admin_label=&#8221;Column&#8221; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; admin_label=&#8221;Column&#8221; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; background_color_phone=&#8221;RGBA(255,255,255,0)&#8221; background_last_edited=&#8221;on|phone&#8221; background_enable_color_phone=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;|700|||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; background_color=&#8221;#ea5504&#8243; width=&#8221;100%&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||||false|false&#8221; custom_margin_tablet=&#8221;&#8221; custom_margin_phone=&#8221;||||false|false&#8221; custom_margin_last_edited=&#8221;on|desktop&#8221; custom_padding=&#8221;10px||||false|false&#8221; link_option_url=&#8221;https:\/\/kyowakirininternational.com\/global-reporting\/&#8221; link_option_url_new_window=&#8221;on&#8221; border_color_all=&#8221;#FFFFFF&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center;\">Report Adverse Event <img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png\" width=\"26\" height=\"28\" alt=\"\" class=\"wp-image-615 alignnone size-full\" \/><\/p>\n<p style=\"text-align: center;\">[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; z_index=&#8221;500&#8243; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; min_height=&#8221;100px&#8221; height=&#8221;100px&#8221; overflow-x=&#8221;visible&#8221; overflow-y=&#8221;visible&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;|||25px|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_menu menu_id=&#8221;37&#8243; active_link_color=&#8221;#ea5504&#8243; dropdown_menu_bg_color=&#8221;#5d6164&#8243; dropdown_menu_line_color=&#8221;#ff3300&#8243; dropdown_menu_text_color=&#8221;#000000&#8243; dropdown_menu_active_link_color=&#8221;#ff3300&#8243; mobile_menu_bg_color=&#8221;#b4c0c1&#8243; mobile_menu_text_color=&#8221;#000000&#8243; logo=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/KyowaKirin_BrandLogo_colorv2-PhotoRoom-1-1024&#215;216.png&#8221; logo_url=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/&#8221; logo_width=&#8221;100%&#8221; logo_max_width=&#8221;17%&#8221; show_search_icon=&#8221;on&#8221; search_icon_color=&#8221;#ea5504&#8243; menu_icon_color=&#8221;#ea5504&#8243; logo_max_width_tablet=&#8221;35%&#8221; logo_max_width_phone=&#8221;76%&#8221; logo_max_width_last_edited=&#8221;on|phone&#8221; show_search_icon_tablet=&#8221;on&#8221; show_search_icon_phone=&#8221;on&#8221; show_search_icon_last_edited=&#8221;on|phone&#8221; search_icon_color_tablet=&#8221;#ea5504&#8243; search_icon_color_phone=&#8221;#ea5504&#8243; search_icon_color_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; menu_font=&#8221;|600|||||||&#8221; menu_text_color=&#8221;#5d6164&#8243; menu_font_size=&#8221;17px&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; custom_css_free_form=&#8221;.et_pb_menu__icon.et_pb_menu__search-button {||padding: 2% 2% 2% 1%;||||}&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_menu][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;90%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-25px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][lwp_divi_breadcrumbs font_icon=&#8221;&#x35;||divi||400&#8243; link_color=&#8221;#5d6164&#8243; separator_color=&#8221;#e95505&#8243; current_text_color=&#8221;#e95505&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; module_text_align=&#8221;left&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; text_orientation=&#8221;left&#8221; animation_style=&#8221;fade&#8221; global_module=&#8221;1047&#8243; global_colors_info=&#8221;{}&#8221;][\/lwp_divi_breadcrumbs][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#5d6164&#8243; height=&#8221;50px&#8221; height_tablet=&#8221;100px&#8221; height_phone=&#8221;140px&#8221; height_last_edited=&#8221;on|phone&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-40px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_menu menu_id=&#8221;39&#8243; menu_style=&#8221;centered&#8221; active_link_color=&#8221;#ea5504&#8243; dropdown_menu_line_color=&#8221;#ea5504&#8243; dropdown_menu_active_link_color=&#8221;#ea5504&#8243; mobile_menu_bg_color=&#8221;#b4c0c1&#8243; mobile_menu_text_color=&#8221;#000000&#8243; menu_icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; menu_text_color=&#8221;#FFFFFF&#8221; menu_font_size=&#8221;15px&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_menu][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; next_background_color=&#8221;#ffffff&#8221; module_id=&#8221;announcements&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#ea5504&#8243; bottom_divider_style=&#8221;slant2&#8243; bottom_divider_height=&#8221;42px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; header_font=&#8221;|700|||||||&#8221; header_text_color=&#8221;#ffffff&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1 style=\"text-align: left\">News &amp; Resources<\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; next_background_color=&#8221;#e5e5e5&#8243; module_id=&#8221;news&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; bottom_divider_style=&#8221;slant2&#8243; bottom_divider_height=&#8221;52px&#8221; bottom_divider_flip=&#8221;horizontal&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; header_2_font=&#8221;|700|||||||&#8221; header_2_text_color=&#8221;#ea5504&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 style=\"text-align: center;\">Latest News<\/h2>\n<p style=\"text-align: left;\">This page is not intended for the general public. News releases issued by Kyowa Kirin are intended to inform media and investors of information related to the company&#8217;s business in a fair manner. Though it may include information concerning pharmaceutical products (including products under development), it is not for the purpose of promoting, advertising or medical advice.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<strong>Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company <\/strong><br \/>\n<a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/10\/Kyowa_Kirin_Announces_Changes_to_Top_Leadership_Positions_October_2024.pdf\" rel=\"attachment noopener wp-att-1677\" target=\"_blank\">Download<\/a><br \/>\n<span class=\"flDate\">31 October 2024<\/span>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin announces positive interim real-world data for mogamulizumab (Poteligeo\u00ae) in cutaneous T-cell lymphoma at EORTC-CLTG 2024<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/10\/Press-Release_EORTC_October-2024-FINAL.pdf\" rel=\"attachment noopener wp-att-1677\" target=\"_blank\">Download<\/a><br \/><span class=\"flDate\">08 October 2024<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/09\/ASBMR-Curtain-Raiser-News-Release_FINAL.pdf\" rel=\"attachment noopener wp-att-1677\" target=\"_blank\">Download<\/a><br \/><span class=\"flDate\">26 September 2024<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphataemia (XLH)<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/09\/100924_XLH-DMP-JBMR-Productivity-Press-Release_KKI_Final.pdf\" rel=\"attachment noopener wp-att-1677\" target=\"_blank\">Download<\/a><br \/><span class=\"flDate\">10 September 2024<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin International and NewBridge Pharmaceuticals enter into agreement to improve access to medicines for rare disease patients across Middle East and North Africa<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/08\/KKI_NewBridge-Press-Release_FINAL-VERSION-002.pdf\" rel=\"attachment noopener wp-att-1677\" target=\"_blank\">Download<\/a><br \/><span class=\"flDate\">07 August 2024<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong><span class=\"FlTitle\">Polish Ministry of Health approves reimbursement of POTELIGEO\u00ae (mogamulizumab) for adults living with mycosis fungoides or S\u00e9zary syndrome.<\/span><\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/07\/PR_EGM_POT_reimbursement_Poland.pdf\" rel=\"attachment noopener wp-att-1677\" target=\"_blank\">Download<\/a><br \/><span class=\"flDate\">31 July 2024<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong><span class=\"FlTitle\">NICE enables access to first treatment that targets the underlying pathophysiology of rare disease X-linked hypophosphataemia (XLH) in adults.<\/span><\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/06\/Press-Release_Crysvita-NICE-Adults-announcement_Certifed_210624.pdf\" rel=\"attachment noopener wp-att-1677\" target=\"_blank\">Download<\/a><br \/><span class=\"flDate\">14 May 2024<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong><span class=\"FlTitle\">CTCL Global Care Collaborative Pioneers Consensus for Improving Diagnosis and Care in Cutaneous T-Cell Lymphoma (CTCL).<\/span><\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/05\/KKI-CTCL_Global_Care_Collaborative-Launch_Press_Release_FINAL.pdf\" rel=\"attachment noopener wp-att-1677\" target=\"_blank\">Download<\/a><br \/><span class=\"flDate\">14 May 2024<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong><span class=\"FlTitle\">First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of MF and SS.<\/span><\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/05\/First_Interim_Analysis_of_PROSPER_Study_Details_Patient-Reported_Symptom_Burden_of_MF_and_SS_APPROVED.pdf\" rel=\"attachment noopener wp-att-1677\" target=\"_blank\">Download<\/a><br \/><span class=\"flDate\">15 April 2024<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases.<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/Final_Kyowa_Kirin_Orchard_Closing_240124-1.pdf\" rel=\"attachment noopener wp-att-1677\" target=\"_blank\">Download<\/a><br \/>24 January 2024<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life.<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/APPROVED_Press-Release_MAVORIC_Post_Hoc_Analysis_HRQoL_December_2023-1.pdf\" rel=\"attachment wp-att-1691\">Download<\/a><br \/>11 December 2023<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin Responds to NICE\u2019s Publication of Appraisal Consultation Document for CRYSVITA\u00ae (Burosumab), for Treatment of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults.<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/PRESS_RELEASE_ACD_press_release_for_burosumab-1.pdf\" rel=\"attachment wp-att-1694\">Download<\/a><br \/>29 November 2023<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin demonstrates commitment to real-world evidence for POTELIGEO\u00ae (mogamulizumab) at EORTC 2023.<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/Press_Release_Sept_23-APPROVED-Real-world_evidence_for_POTELIGEO_mogamulizumab_at_EORTC_2023_002-1.pdf\" rel=\"attachment wp-att-1762\">Download<\/a><br \/>21 September 2023<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Gr\u00fcnenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration.<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/KKI_GRT_JVC_deal_close_PR_2023.pdf\" rel=\"attachment wp-att-1761\">Download<\/a><br \/>2 August 2023<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Scottish Medicines Consortium (SMC) Enables Access to First Treatment Tackling the Underlying Cause of X-Linked Hypophosphataemia (XLH) in Adults.<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/CRYSVITA_Adults_SMC_press_release-1.pdf\" rel=\"attachment wp-att-1760\">Download<\/a><br \/>13 February 2023<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Gr\u00fcnenthal and Kyowa Kirin International announce Joint Venture Collaboration for established medicines portfolio.<\/strong><br \/>24 November 2022<br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/2022_november_kki_press_release-1.pdf\" rel=\"attachment wp-att-1839\">Download<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin Appoints Abdul Mullick, President, Kyowa Kirin International, to New Global Role as Vice Chief International Business Officer; Jeremy Morgan appointed President, Kyowa Kirin International<\/strong><br \/>08 November 2022<br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/2022_kki_press_release-1.pdf\" rel=\"attachment wp-att-1838\">Download<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin receives European Commission Approval for Use of CRYSVITA\u00ae\u25bc(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO).<\/strong><br \/>18 August 2022<br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/180822_CRYSVITA-TIO-EC-Approval-Press-Release_FOR-WEBSITE-UPLOAD-1.pdf\" rel=\"attachment wp-att-1837\">Download<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA\u00ae \u25bc(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO).<\/strong><br \/>28 June 2022<br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/CRYSVITA-TIO-CHMP-Opinion-Press-Release-3-FOR-WEBSITE-UPLOAD-1.pdf\" rel=\"attachment wp-att-1835\">Download<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>New Real World Evidence Underlines Benefits of POTELIGEO\u00ae\u25bc (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients.<\/strong><br \/>14 October 2021<br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/New_Real_World_Evidence_Underlines_Benefits_of_POTELIGEO-1.pdf\" rel=\"attachment wp-att-1833\">Download<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Long-term CRYSVITA\u00ae \u25bc (burosumab) treatment reduces the burden of disease in adults with X-Linked Hypophosphataemia (XLH), a rare genetic metabolic bone disease.<\/strong><br \/>24 September 2021<br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/Press-release-new-CRYSVITA-data-published-in-RMD-Open-CERTIFIED-1.pdf\" rel=\"attachment wp-att-1831\">Download<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin Announces EU Approval for the Self-administration of CRYSVITA\u00ae \u25bc (burosumab) to Treat X-Linked Hypophosphataemia (XLH)<\/strong><br \/>19 July 2021<br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/KyowaKirin_Announces_Treat_X-Linked_Hypophosphataemia_-XLH-1.pdf\" rel=\"attachment wp-att-1830\">Download<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin welcomes the decision that the National Institute for Health and Care Excellence will revisit their appraisal <\/strong><strong>of the innovative systemic treatment, POTELIGEO\u00ae (mogamulizumab), for adults living with two forms of ultra-rare non-Hodgkin lymphoma.<\/strong><br \/>11 June 2021<br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/APPROVED-FOR-DISTRIBUTION-KK-UK-Poteligeo-NICE-Appeal-Decision-Press-Release-1.pdf\" rel=\"attachment wp-att-1829\">Download<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients.<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/EHA-Zinzani-abstract-press-release-1.pdf\" rel=\"attachment wp-att-1828\">Download<\/a><br \/>11 June 2021<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin Receives Positive CHMP Opinion for the Self-administration of CRYSVITA\u00ae \u25bc (burosumab) to Treat X-Linked Hypophosphataemia (XLH), a Rare Metabolic Bone Disorder.<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/CRYSVITA_CHMP_ve_opinion_self-admin_press_release-1.pdf\" rel=\"attachment wp-att-1826\">Download<\/a><br \/>07 May 2021<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin responds to the National Institute for Health and Care Excellence (NICE) decision to not provide people living with certain rare blood cancers access to POTELIGEO\u00ae (mogamulizumab).<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/030321_Press_Release_UK-Mogamulizumab-1.pdf\" rel=\"attachment wp-att-1825\">Download<\/a><br \/>04 March 2021<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_icon font_icon=&#8221;&#xf1c1;||fa||900&#8243; icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_icon][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Kyowa Kirin Receives Positive CHMP Opinion for the Expanded Use of CRYSVITA\u00ae (burosumab) to Include Older Adolescents and Adults for the Treatment of X-Linked Hypophosphataemia (XLH).<\/strong><br \/><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/Positive-CHMP-Opinion-1.pdf\" rel=\"attachment wp-att-1823\">Download<\/a><br \/>24 July 2020<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; next_background_color=&#8221;#FFFFFF&#8221; module_id=&#8221;social&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#e5e5e5&#8243; bottom_divider_style=&#8221;slant2&#8243; bottom_divider_height=&#8221;47px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; header_2_font=&#8221;|700|||||||&#8221; header_2_text_color=&#8221;#ea5504&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 style=\"text-align: center\">Social Media<\/h2>\n<p style=\"text-align: left\">[\/et_pb_text][et_pb_code _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<!-- [et_pb_line_break_holder] --><script src=\"https:\/\/static.elfsight.com\/platform\/platform.js\" data-use-service-core defer><\/script><!-- [et_pb_line_break_holder] --><\/p>\n<div class=\"elfsight-app-7b581d73-8824-436e-bbb0-f9619dab5f41\" data-elfsight-app-lazy><\/div>\n<p>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_id=&#8221;stories&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; header_2_font=&#8221;|700|||||||&#8221; header_2_text_color=&#8221;#ea5504&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 style=\"text-align: center\">Stories<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_blurb url=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/International-Womens-Day-1.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/Carousel-3-1-300&#215;157.png&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; header_level=&#8221;h3&#8243; text_orientation=&#8221;center&#8221; link_option_url=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/International-Womens-Day-1.pdf&#8221; link_option_url_new_window=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_blurb][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_blurb url=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/International-day-of-persons-with-disabilities-1.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/International-day-of-persons-with-disabilities-1.jpg&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; header_level=&#8221;h3&#8243; text_orientation=&#8221;center&#8221; link_option_url=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/International-day-of-persons-with-disabilities-1.pdf&#8221; link_option_url_new_window=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_blurb][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_blurb url=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/04\/Rare-Disease-Month-1-1.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/Rare-disease-day-banner-1.jpg&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; header_level=&#8221;h3&#8243; text_orientation=&#8221;center&#8221; link_option_url=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/04\/Rare-Disease-Month-1-1.pdf&#8221; link_option_url_new_window=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_blurb][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#5d6164&#8243; custom_margin=&#8221;||||false|false&#8221; top_divider_style=&#8221;curve&#8221; top_divider_color=&#8221;#FFFFFF&#8221; top_divider_height=&#8221;71px&#8221; top_divider_repeat=&#8221;1x&#8221; top_divider_flip=&#8221;vertical&#8221; top_divider_style_tablet=&#8221;&#8221; top_divider_style_phone=&#8221;none&#8221; top_divider_style_last_edited=&#8221;on|desktop&#8221; global_module=&#8221;3452&#8243; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;70%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-50px||||false|false&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/KKI-Logo-White-PhotoRoom-1-300&#215;86.png&#8221; title_text=&#8221;KKI Logo White-PhotoRoom&#8221; align=&#8221;center&#8221; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;200px&#8221; width_tablet=&#8221;15%&#8221; width_phone=&#8221;50%&#8221; width_last_edited=&#8221;on|phone&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_2,1_6,1_6,1_6&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;70%&#8221; max_width=&#8221;100%&#8221; custom_padding=&#8221;||27px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; header_4_text_color=&#8221;#FFFFFF&#8221; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; custom_padding=&#8221;5px|10px|5px|10px|false|false&#8221; border_width_all=&#8221;1px&#8221; border_color_all=&#8221;#FFFFFF&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center\"><span style=\"color: #ffffff\"><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/global-reporting\/\" title=\"Report an Adverse Event\" target=\"_blank\" style=\"color: #ffffff\" rel=\"noopener\">ADVERSE EVENTS SHOULD BE REPORTED HERE<\/a><\/span><\/p>\n<p>[\/et_pb_text][et_pb_text content_tablet=&#8221;&#8221; content_phone=&#8221;&#8221; content_last_edited=&#8221;on|phone&#8221; module_class=&#8221;my-popup2&#8243; _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;||||||||&#8221; text_text_color=&#8221;#E02B20&#8243; text_orientation=&#8221;center&#8221; custom_margin=&#8221;||||false|false&#8221; custom_margin_tablet=&#8221;&#8221; custom_margin_phone=&#8221;-50px||||false|false&#8221; custom_margin_last_edited=&#8221;on|desktop&#8221; custom_padding=&#8221;||||false|false&#8221; text_font_size_tablet=&#8221;&#8221; text_font_size_phone=&#8221;&#8221; text_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: left;\"><span style=\"color: #ffffff;\"><a href=\"https:\/\/clinicaltrials.gov\/search?term=Kyowa%20Kirin&#038;city=\" target=\"_blank\" rel=\"noopener\" title=\"Clinical Trials\" style=\"color: #ffffff;\">Click here to search for Kyowa Kirin\u2019s clinical trials<\/a><\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_6&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span style=\"color: #ffffff\"><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#press\" style=\"color: #ffffff\">Press &amp; Media<\/a><\/span><br \/><span style=\"color: #ffffff\"><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/people-careers\/\" style=\"color: #ffffff\">Careers<\/a><\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_6&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_font_size=&#8221;16px&#8221; text_text_color_tablet=&#8221;&#8221; text_text_color_phone=&#8221;&#8221; text_text_color_last_edited=&#8221;on|desktop&#8221; global_colors_info=&#8221;{}&#8221; text_text_color__hover_enabled=&#8221;on|desktop&#8221; text_text_color__hover=&#8221;#FFFFFF&#8221;]<\/p>\n<p><span style=\"color: #ffffff;\"><a href=\"https:\/\/kyowakirininternational.com\/global-reporting\/\" target=\"_blank\" style=\"color: #ffffff;\" rel=\"noopener\">Reporting<\/a><\/span><br \/><span style=\"color: #ffffff;\"><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/who-we-are\/responsibility\" style=\"color: #ffffff;\">Responsibility<\/a><\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_6&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;70%&#8221; max_width=&#8221;100%&#8221; custom_padding=&#8221;||27px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; header_text_color=&#8221;#FFFFFF&#8221; header_4_text_color=&#8221;#FFFFFF&#8221; header_6_text_color=&#8221;#FFFFFF&#8221; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/who-we-are\/\">ABOUT US<\/a>\u00a0 |\u00a0 <a href=\"https:\/\/kyowakirininternational.com\/noba-en\/contact-us\/\">CONTACT US<\/a>\u00a0 |\u00a0 <a href=\"https:\/\/kyowakirininternational.com\/noba-en\/notices\/\" title=\"Notices\">NOTICES<\/a>\u00a0 |\u00a0 <a href=\"https:\/\/kyowakirininternational.com\/noba-en\/notices\/\" title=\"Terms of Use\">TERMS OF USE<\/a><\/h4>\n<h4><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/notices\/\" title=\"Modern Slavery Act\">MODERN SLAVERY ACT<\/a> | <a href=\"https:\/\/kyowakirininternational.com\/noba-en\/notices\/\" title=\"Third Party Code of Conduct\">THIRD PARTY CODE OF CONDUCT<\/a><\/h4>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;70%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-50px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span>Copyright \u00a9 Kyowa Kirin International plc. All rights reserved. This website is developed and funded by Kyowa Kirin International plc.<\/span><\/p>\n<p>Head Office Nordics &amp; Baltics:<br \/>Kyowa Kirin AB<br \/>Torshamnsgatan 39<br \/>164 40 Kista<br \/>Sweden<br \/>Tel: + 46 (8) 50 90 74 10<\/p>\n<p>Kyowa Kirin International plc is a company registered in Scotland (company number SC198780) with registered address at Galabank Business Park, Galashiels TD1 1QH, United Kingdom.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#5d6164&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; width=&#8221;70%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-100px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]KKI\/NORD\/KKI\/0049 April 2025[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This page is not intended for the general public. News releases issued by Kyowa Kirin are intended to inform media and investors of information related to the company\u2019s business in a fair manner. Though it may include information concerning pharmaceutical products (including products under development), it is not for the purpose of promoting, advertising or medical advice.<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":31,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-923","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Industry News and Resources | Kyowa Kirin<\/title>\n<meta name=\"description\" content=\"Read the latest news from the industry\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News &amp; Resources\" \/>\n<meta property=\"og:description\" content=\"Read the latest news from the industry\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/\" \/>\n<meta property=\"og:site_name\" content=\"Kyowa Kirin International - NOBA\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-23T11:49:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"26\" \/>\n\t<meta property=\"og:image:height\" content=\"28\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/\",\"url\":\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/\",\"name\":\"Industry News and Resources | Kyowa Kirin\",\"isPartOf\":{\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png\",\"datePublished\":\"2024-02-01T14:24:29+00:00\",\"dateModified\":\"2025-04-23T11:49:42+00:00\",\"description\":\"Read the latest news from the industry\",\"breadcrumb\":{\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#primaryimage\",\"url\":\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png\",\"contentUrl\":\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png\",\"width\":26,\"height\":28},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kyowakirininternational.com\/noba-en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &amp; Resources\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/#website\",\"url\":\"https:\/\/kyowakirininternational.com\/noba-en\/\",\"name\":\"Kyowa Kirin International - NOBA\",\"description\":\"A Specialty Pharmaceutical Company\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kyowakirininternational.com\/noba-en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Industry News and Resources | Kyowa Kirin","description":"Read the latest news from the industry","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/","og_locale":"en_GB","og_type":"article","og_title":"News &amp; Resources","og_description":"Read the latest news from the industry","og_url":"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/","og_site_name":"Kyowa Kirin International - NOBA","article_modified_time":"2025-04-23T11:49:42+00:00","og_image":[{"width":26,"height":28,"url":"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/","url":"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/","name":"Industry News and Resources | Kyowa Kirin","isPartOf":{"@id":"https:\/\/kyowakirininternational.com\/noba-en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#primaryimage"},"image":{"@id":"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#primaryimage"},"thumbnailUrl":"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png","datePublished":"2024-02-01T14:24:29+00:00","dateModified":"2025-04-23T11:49:42+00:00","description":"Read the latest news from the industry","breadcrumb":{"@id":"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#primaryimage","url":"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png","contentUrl":"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png","width":26,"height":28},{"@type":"BreadcrumbList","@id":"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kyowakirininternational.com\/noba-en\/"},{"@type":"ListItem","position":2,"name":"News &amp; Resources"}]},{"@type":"WebSite","@id":"https:\/\/kyowakirininternational.com\/noba-en\/#website","url":"https:\/\/kyowakirininternational.com\/noba-en\/","name":"Kyowa Kirin International - NOBA","description":"A Specialty Pharmaceutical Company","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kyowakirininternational.com\/noba-en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/pages\/923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/comments?post=923"}],"version-history":[{"count":38,"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/pages\/923\/revisions"}],"predecessor-version":[{"id":3539,"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/pages\/923\/revisions\/3539"}],"wp:attachment":[{"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/media?parent=923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}